The persistence of subcutaneous infliximab is equivalent to intravenous form in patients with inflammatory bowel diseases

被引：0
|
作者：
Bothorel, L. [1 ]
Laharie, D. [1 ]
Poullenot, F. [1 ]
Gohier, E. [1 ]
Chevrier, C. [1 ]
Berger, A. [1 ]
Zerbib, F. [1 ]
Riviere, P. [1 ]
机构：
[1] Bordeaux Univ Hosp, Dept Gastroenterol, Bordeaux, France
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P805
引用
收藏
页码：I1490 / I1490
页数：1
相关论文
共 50 条
  • [1] Persistence of subcutaneous infliximab after two years of the switch from intravenous infliximab to subcutaneous infliximab in Inflammatory Bowel Disease patients
    Huguet, J. M.
    Iborra, M.
    Marti, L.
    Bosca-Watts, M. M.
    Ramirez, J. J.
    Ruiz, L.
    Sanchis, L.
    Garrido, A.
    Alemany, G.
    Suria, C.
    Paredes, J. M.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1242 - I1242
  • [2] Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study
    Buisson, Anthony
    Nachury, Maria
    Reymond, Maud
    Yzet, Clara
    Wils, Pauline
    Payen, Laure
    Laugie, Marie
    Manlay, Luc
    Mathieu, Nicolas
    Pereira, Bruno
    Fumery, Mathurin
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (09) : 2338 - 2346
  • [3] Comparison of subcutaneous and intravenous infliximab in patients with inflammatory bowel disease showed no differences in immunogenicity or treatment persistence at one year
    Hancox, S.
    Morda, F.
    Black, C.
    Selinger, C.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1836 - I1836
  • [4] Comparison of subcutaneous and intravenous infliximab in patients with inflammatory bowel disease showed no differences in immunogenicity or treatment persistence at 1 year
    Hancox, Sarah
    Morda, Francesco
    Black, Christopher J.
    Selinger, Christian Philipp
    FRONTLINE GASTROENTEROLOGY, 2025, 16 (01) : 11 - 19
  • [5] COMPARISON OF SUBCUTANEOUS AND INTRAVENOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE SHOWED NO DIFFERENCES IN IMMUNOGENICITY OR TREATMENT PERSISTENCE AT ONE YEAR
    Morda, F.
    Hancox, S.
    Black, C. J.
    Selinger, C.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S239 - S239
  • [6] Transition from intravenous to subcutaneous infliximab: effectiveness in a cohort of patients with inflammatory bowel disease
    Todeschini, A.
    Geccherle, A.
    Signoretto, P.
    Colaci, N.
    Barugola, G.
    Variola, A.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1631 - I1631
  • [7] Clinical Validation of a Novel Software Tool to Guide the Intravenous-to-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases
    Hoffert, Yannick
    Wang, Zhigang
    Fumery, Mathurin
    Nachury, Maria
    Bazoge, Maeva
    Buisson, Anthony
    Dreesen, Erwin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S921 - S922
  • [8] Switch from intravenous to subcutaneous infliximab in patients with Inflammatory Bowel Disease: efficacy, safety and patients' acceptance
    Oliva, B. Caballol
    Fernandez-Clotet, A.
    Panes, J.
    Masamunt, M. C.
    Gallego, M.
    Barastegui, R.
    Vara, A.
    Giner, A.
    Ricart, E.
    Ordas, I.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 618 - 618
  • [9] Effectiveness of Switching to Subcutaneous Infliximab in Pediatric Inflammatory Bowel Disease Patients on Intravenous Maintenance Therapy
    Gianolio, Laura
    Armstrong, Katherine
    Swann, Ewan
    Shepherd, Rhona
    Henderson, Paul
    Wilson, David C. C.
    Russell, Richard K. K.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2023, 77 (02): : 235 - 239
  • [10] From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative
    Verma, Ajay M.
    Patel, Anusha
    Subramanian, Sreedhar
    Smith, Philip J.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (02): : 88 - 89
12345